Kintara Therapeutics: Stockholders Must Vote by 11:59 P.M., ET on Sept 19 for Vote to Count >KTRA
Kintara Therapeutics Announces Special Meeting for TuHURA Merger
Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties
Express News | Tuhura Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for Vista-101 Clinical Trial Evaluating Kva12123 in Patients With Advanced Solid Tumor Cancer
Kintara Therapeutics Eyes Acquisition Amidst Cautionary Advice
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
Express News | Kintara Therapeutics Inc - Under Terms of Agreement, Tuhura Will Pay Kineta $5.0 Mln
Express News | Tuhura Biosciences Enters Into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s Kva12123 Novel Anti-Vista Checkpoint Inhibitor
Kintara Therapeutics Outlines Progress and Potential Risks
Express News | Kintara Therapeutics and Tuhura Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Chegg Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Express News | Kintara Therapeutics Inc - Received a Letter From Nasdaq Advising That Company Had Been Granted a 180-Day Extension to December 9
Express News | Kintara Therapeutics:On June 4,Co Submitted Request to Nasdaq for Additional 180-Day Extension to Regain Compliance With Minimum Bid Price Requirement
12 Health Care Stocks Moving In Tuesday's Intraday Session
Express News | Kintara Therapeutics Inc: Phase 3 Trial Is Expected to Begin Enrollment in 2H 2024
Express News | Kintara Therapeutics Inc: Tuhura's Lead Candidate, Ifx-2.0, Was Safe and Well Tolerated at Once Weekly Dosing for 3 Weeks
Express News | Tuhura Biosciences and Kintara Therapeutics Announce Positive Results From Phase 1B Trial of Ifx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (Mcc) and Cutaneous Squamous Cell Carcinoma (Cscc)
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
No Data